AIM ImmunoTech Inc.

0.8400+0.0100+1.20%Vol 78.05K1Y Perf -62.27%
Jun 24th, 2022 16:00 DELAYED
BID0.8348 ASK0.8740
Open0.8500 Previous Close0.8300
Pre-Market- After-Market0.83
 - -  -0.01 -1.19%
Target Price
3.00 
Analyst Rating
Strong Buy 1.00
Potential %
257.14 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     60.49
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     55.23
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
17.37 
Earnings Rating
Market Cap33.34M 
Earnings Date
16th Aug 2022
Alpha-0.01 Standard Deviation0.27
Beta-0.58 

Today's Price Range

0.82840.8650

52W Range

0.55002.22

5 Year PE Ratio Range

-1.70-1.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
3.70%
1 Month
-6.87%
3 Months
-24.32%
6 Months
-23.64%
1 Year
-62.27%
3 Years
-80.56%
5 Years
-96.10%
10 Years
-99.95%

TickerPriceChg.Chg.%
AIM0.84000.01001.20
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
60.30
65.80
0.00
0.00
-1 138.30
Leverage Ratio 1.00
ProfitabilityValueIndustryS&P 500US Markets
-392.90
-13 822.10
-13 410.00
-6 361.50
-
RevenueValueIndustryS&P 500US Markets
139.00K
0.00
-16.96
-12.96
Earnings HistoryEstimateReportedSurprise %
Q03 2021--0.08-
Q02 2021--0.12-
Q01 2021--0.08-
Q04 2020--0.09-
Q03 2020--0.08-
Q02 2020--0.11-
Q01 2020--0.22-
Q03 2019--1.13-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date16th Aug 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume78.05K
Shares Outstanding39.69K
Shares Float47.43M
Trades Count247
Dollar Volume66.19K
Avg. Volume278.47K
Avg. Weekly Volume145.72K
Avg. Monthly Volume179.80K
Avg. Quarterly Volume509.90K

AIM ImmunoTech Inc. (AMEX: AIM) stock closed at 0.84 per share at the end of the most recent trading day (a 1.2% change compared to the prior day closing price) with a volume of 78.05K shares and market capitalization of 33.34M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 23 people. AIM ImmunoTech Inc. CEO is Thomas K. Equels.

The one-year performance of AIM ImmunoTech Inc. stock is -62.27%, while year-to-date (YTD) performance is -8.7%. AIM stock has a five-year performance of -96.1%. Its 52-week range is between 0.55 and 2.22, which gives AIM stock a 52-week price range ratio of 17.37%

AIM ImmunoTech Inc. currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 0.74, a price-to-sale (PS) ratio of 231.29, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -31.21%, a ROC of -30.91% and a ROE of -32.57%. The company’s profit margin is -%, its EBITDA margin is -13 410.00%, and its revenue ttm is $139.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from AIM ImmunoTech Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. AIM ImmunoTech Inc.’s next earnings report date is 16th Aug 2022.

The consensus rating of Wall Street analysts for AIM ImmunoTech Inc. is Strong Buy (1), with a target price of $3, which is +257.14% compared to the current price. The earnings rating for AIM ImmunoTech Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AIM ImmunoTech Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AIM ImmunoTech Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.99, ATR14 : 0.06, CCI20 : -47.40, Chaikin Money Flow : -0.48, MACD : -0.04, Money Flow Index : 65.57, ROC : -3.55, RSI : 42.14, STOCH (14,3) : 27.34, STOCH RSI : 1.00, UO : 28.68, Williams %R : -72.66), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AIM ImmunoTech Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

CEO: Thomas K. Equels

Telephone: +1 352 448-7797

Address: 2117 SW Highway 484, Ocala 34473, FL, US

Number of employees: 23

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

62%38%

Bearish Bullish

62%38%

Bearish Bullish

65%35%

TipRanks News for AIM

Thu, 19 May 2022 14:25 GMT AIM ImmunoTech (AIM) Has a New Rating from Maxim Group

- TipRanks. All rights reserved.

News

Stocktwits